Therefore, PDE5-Is has poor efficacy in patients lacking upstream nitric oxide (NO) pathway (29) in some disease states, such as diabetes with peripheral neuropathy (30) and prostate cancer (31). Here, PDE5A is linked to Familial prostate cancer.